PD-1 Antibody

13 clinical trials · Condition

Record	Firm	Date
Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma (NCT05461235)	China Medical University, China	2022-07-15
Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer (NCT05156788)	Shanghai Zhongshan Hospital	2021-12-12
PD-1 Antibody Improve Mixed Chimerism (NCT04944511)	Beijing Friendship Hospital	2021-07-01
Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC (NCT04507217)	Sun Yat-sen University	2020-09-15
A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC (NCT04108013)	Xuanwu Hospital, Beijing	2019-10-08
Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer (NCT03777124)	Jiangsu HengRui Medicine Co., Ltd.	2019-07-11
A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC (NCT03668496)	Jiangsu HengRui Medicine Co., Ltd.	2018-11-09
PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (NCT02873390)	Ningbo Cancer Hospital	2016-08-01
PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach) (NCT02862028)	Shanghai International Medical Center	2016-08-01

Every clearance here is in the API, with alerts when new ones post.